Literature DB >> 2927398

Somatic mutation and transcriptional deregulation of myc in endemic Burkitt's lymphoma disease: heptamer-nonamer recognition mistakes?

B Morse1, V J South, P G Rothberg, S M Astrin.   

Abstract

We examined the structure and expression of the myc protooncogene in DNA extracted from a primary (uncultured) endemic Burkitt's lymphoma sample designated eBL3. Dot and Northern (RNA) blot analyses demonstrated extreme levels of myc RNA in the eBL3 sample. Nearly complete sequence data of the altered myc locus isolated from eBL3 DNA demonstrated extensive mutations (duplications, insertions, and deletions) in critical myc regulatory regions. Taken together, the data support the idea that myc transcriptional deregulation in Burkitt's lymphoma disease may be a consequence of the position and number of mutations produced within and around the myc locus. Furthermore, the myc exon-1-intron-1 hypermutable PvuII site is part of a potential heptamer-nonamer recognition sequence, suggesting a mechanism for mutation in endemic Burkitt's lymphoma disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2927398      PMCID: PMC362147          DOI: 10.1128/mcb.9.1.74-82.1989

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  40 in total

1.  Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.

Authors:  P S Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

2.  Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis.

Authors:  W S Hayward; B G Neel; S M Astrin
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

Review 3.  Specific chromosomal translocations and the genesis of B-cell-derived tumors in mice and men.

Authors:  G Klein
Journal:  Cell       Date:  1983-02       Impact factor: 41.582

4.  New M13 vectors for cloning.

Authors:  J Messing
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

Review 5.  Somatic generation of antibody diversity.

Authors:  S Tonegawa
Journal:  Nature       Date:  1983-04-14       Impact factor: 49.962

Review 6.  Phenotypic and cytogenetic characteristics of human B-lymphoid cell lines and their relevance for the etiology of Burkitt's lymphoma.

Authors:  K Nilsson; G Klein
Journal:  Adv Cancer Res       Date:  1982       Impact factor: 6.242

7.  Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus.

Authors:  A C Hayday; S D Gillies; H Saito; C Wood; K Wiman; W S Hayward; S Tonegawa
Journal:  Nature       Date:  1984 Jan 26-Feb 1       Impact factor: 49.962

8.  Identification and nucleotide sequence of a human locus homologous to the v-myc oncogene of avian myelocytomatosis virus MC29.

Authors:  W W Colby; E Y Chen; D H Smith; A D Levinson
Journal:  Nature       Date:  1983-02-24       Impact factor: 49.962

9.  Expression of cellular homologues of retroviral onc genes in human hematopoietic cells.

Authors:  E H Westin; F Wong-Staal; E P Gelmann; R Dalla-Favera; T S Papas; J A Lautenberger; A Eva; E P Reddy; S R Tronick; S A Aaronson; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

10.  Nucleotide sequence of the human c-myc locus: provocative open reading frame within the first exon.

Authors:  C Gazin; S Dupont de Dinechin; A Hampe; J M Masson; P Martin; D Stehelin; F Galibert
Journal:  EMBO J       Date:  1984-02       Impact factor: 11.598

View more
  2 in total

1.  c-myc overexpression is a tumor-specific phenomenon in a subset of human colorectal carcinomas.

Authors:  A Viel; R Maestro; G Toffoli; G Grion; M Boiocchi
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  Long-distance activation of the Myc protooncogene by provirus insertion in Mlvi-1 or Mlvi-4 in rat T-cell lymphomas.

Authors:  P A Lazo; J S Lee; P N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.